Literature DB >> 20580267

Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation.

James P Woodrow1, Oksana A Shlobin, Scott D Barnett, Nelson Burton, Steven D Nathan.   

Abstract

BACKGROUND: The radiographic presence of allograft infiltrates is atypical of bronchiolitis obliterans (BO) and inconsistent with the definition of bronchiolitis obliterans requires that restrictive processes are ruled out. The natural history of these other forms of chronic allograft dysfunction has not been well characterized. We examined the prognostic significance of radiographic and spirometric restrictive processes in comparison to BOS among lung transplant recipients.
METHODS: We performed a retrospective review of lung transplant recipients with chronic lung allograft dysfunction (CLAD) as defined by spirometry. Subgroups based on the presence or absence of persistent radiographic abnormalities were labeled as non-specific (CLAD-NS) and CLAD due to BOS (CLAD-BOS), respectively. The CLAD-BOS group was further divided into obstructive (OBOS) and restrictive (RBOS) phenotypes based on spirometry. Groups were compared with respect to survival and decline in forced expiratory volume in 1 second (FEV(1)).
RESULTS: Among 241 lung transplant recipients, 96 (40%) were identified as having CLAD, of whom 62 (65%) had CLAD-BOS and 34 (35%) CLAD-NS. No difference between groups was identified with respect to post-CLAD survival or decline in FEV(1). CLAD-BOS subgroups included 35 (56%) patients with OBOS and 27 (44%) with RBOS. There was no difference in these subgroups with respect to survival or subsequent FEV(1) decline.
CONCLUSIONS: Patients with CLAD and persistent radiographic infiltrates have a similar prognosis to BOS patients but may still represent a clinically distinct phenotype. BOS patients frequently exhibited a restrictive pattern on spirometry, which also did not offer further prognostic information, but could still represent a unique disease phenotype. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20580267     DOI: 10.1016/j.healun.2010.05.012

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  20 in total

1.  Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.

Authors:  Hrishikesh S Kulkarni; Wida S Cherikh; Daniel C Chambers; Victoria C Garcia; Ramsey R Hachem; Daniel Kreisel; Varun Puri; Benjamin D Kozower; Derek E Byers; Chad A Witt; Jennifer Alexander-Brett; Patrick R Aguilar; Laneshia K Tague; Yuka Furuya; G Alec Patterson; Elbert P Trulock; Roger D Yusen
Journal:  J Heart Lung Transplant       Date:  2018-09-25       Impact factor: 10.247

Review 2.  Immunosuppression and allograft rejection following lung transplantation: evidence to date.

Authors:  Gregory I Snell; Glen P Westall; Miranda A Paraskeva
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

3.  Restrictive allograft syndrome after lung transplantation: new radiological insights.

Authors:  Adriana Dubbeldam; Caroline Barthels; Johan Coolen; Johny A Verschakelen; Stijn E Verleden; Robin Vos; Geert M Verleden; Walter De Wever
Journal:  Eur Radiol       Date:  2016-11-22       Impact factor: 5.315

4.  Radiological patterns of primary graft dysfunction after lung transplantation evaluated by 64-multi-slice computed tomography: a descriptive study.

Authors:  Esther Okeke Belmaati; Ida Steffensen; Claus Jensen; Klaus F Kofoed; Jann Mortensen; Michael B Nielsen; Martin Iversen
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-28

5.  Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients.

Authors:  Ariss DerHovanessian; Jamie L Todd; Alice Zhang; Ning Li; Aradhna Mayalall; C Ashley Finlen Copeland; Michael Shino; Elizabeth N Pavlisko; W Dean Wallace; Aric Gregson; David J Ross; Rajan Saggar; Joseph P Lynch; John Belperio; Laurie D Snyder; Scott M Palmer; S Sam Weigt
Journal:  Ann Am Thorac Soc       Date:  2016-05

Review 6.  Chronic lung allograft dysfunction phenotypes and treatment.

Authors:  Stijn E Verleden; Robin Vos; Bart M Vanaudenaerde; Geert M Verleden
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 7.  The role of the immune system in lung transplantation: towards improved long-term results.

Authors:  Ramsey R Hachem
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

8.  Longitudinal Forced Vital Capacity Monitoring as a Prognostic Adjunct after Lung Transplantation.

Authors:  Elizabeth A Belloli; Xin Wang; Susan Murray; Ginia Forrester; Adrian Weyhing; Jules Lin; Tammy Ojo; Vibha N Lama
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

9.  Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction.

Authors:  Jamie L Todd; Rahil Jain; Elizabeth N Pavlisko; C Ashley Finlen Copeland; John M Reynolds; Laurie D Snyder; Scott M Palmer
Journal:  Am J Respir Crit Care Med       Date:  2014-01-15       Impact factor: 21.405

10.  Managing bronchiolitis obliterans syndrome (BOS) and chronic lung allograft dysfunction (CLAD) in children: what does the future hold?

Authors:  Gregory I Snell; Miranda Paraskeva; Glen P Westall
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.